{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:16:57Z","timestamp":1794935817801,"version":"4.9.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["20170541028"],"award-info":[{"award-number":["20170541028"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703756"],"award-info":[{"award-number":["81703756"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Liquidambaris Fructus is the infructescences of <jats:italic>Liquidambar formosana<\/jats:italic> Hance and it has been used to treat some breast disease in Traditional Chinese Medicine. In the previous study we found the anti-breast cancer effect of triterpenoid in Liquidambaris Fructus. This study is a further investigation of the triterpenoids in Liquidambaris Fructus and aims to identify their anti-breast cancer targets, meanwhile, to estimate the rationality of the traditional applications of Liquidambaris Fructus.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Triterpenoids in Liquidambaris Fructus were isolated and their structures were identified by NMR spectrums. Potential targets of these triterpenoids were predicted using a reverse pharmacophore mapping strategy. Associations between these targets and the therapeutic targets of breast cancer were analyzed by constructing protein-protein interaction network, and targets played important roles in the network were identified using Molecular Complex Detection method. Binding affinity between the targets and triterpenoids was studied using molecular docking method. Gene ontology enrichment analysis was conducted to reveal the biological process and signaling pathways that the identified targets were involved in.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirteen triterpenoids were identified and 6 of them were the first time isolated from Liquidambaris Fructus. Predicted ADME properties revealed a good druggability of these triterpenoids. We identified 18 protein targets which were closely related to breast cancer progression, especially triple-negative, basal-like or advanced stage breast cancers. The triterpenoids could bind with these targets as their inhibitors: hydrophobic skeleton is a favorable factor for them to stabilize at binding site and polar C17- or C3- substituent was necessary for binding. GO enrichment analysis indicated that inhibition of protein tyrosine kinases autophosphorylation might be the primary mechanism for the anti-breast cancer effect of the triterpenoids, and ErbB4 and EGFR were the most relevant targets.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The study revealed that triterpenoids from Liquidambaris Fructus might exert anti-breast cancer effect by directly inhibit multiple protein targets and signaling pathways, especially ErbB4 and EGFR and related pathways. This study also brings up another hint that the traditional applications of Liquidambaris Fructus on hypogalactia should be reassessed systematically because it might suppress rather than promote lactation by inhibiting the activity of ErbB4.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12906-020-03143-8","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T09:06:18Z","timestamp":1606467978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Identification of the anti-breast cancer targets of triterpenoids in Liquidambaris Fructus and the hints for its traditional applications"],"prefix":"10.1186","volume":"20","author":[{"given":"Ping","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ting","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Fang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"key":"3143_CR1","volume-title":"Pharmacopoeia of the People\u2019s Republic of China","author":"Chinese Pharmacopoeia Commission","year":"2015","unstructured":"Chinese Pharmacopoeia Commission. Pharmacopoeia of the People\u2019s Republic of China, vol. I. Beijing: China Medical Science and Technology Press; 2015."},{"key":"3143_CR2","first-page":"8","volume":"28","author":"Y Li","year":"2019","unstructured":"Li Y, Gong X, Ding X. Research on the law of Chinese medicine in the treatment of early lactation acute mastitis. Chin J Ethnomed Ethnopharm. 2019;28:8\u201310,16.","journal-title":"Chin J Ethnomed Ethnopharm"},{"key":"3143_CR3","first-page":"70","volume":"31","author":"J Xu","year":"2017","unstructured":"Xu J, Wang F, Li Z, Chen J. Randomized parallel control study of Chupixiaoyi granule combined drug lavage treatment on nipple discharge mammary duct ectasia. J Pract Tradit Chin Intern Med. 2017;31:70\u20133.","journal-title":"J Pract Tradit Chin Intern Med"},{"key":"3143_CR4","first-page":"12","volume":"27","author":"X Du","year":"2013","unstructured":"Du X. The flat by Sanjie powder in the treatment of breast cystic hyperplasia randomized parallel controlled study. J Pract Tradit Chin Intern Med. 2013;27:12\u20133.","journal-title":"J Pract Tradit Chin Intern Med"},{"key":"3143_CR5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"3143_CR6","first-page":"254","volume":"20","author":"XT Mu","year":"2017","unstructured":"Mu XT, Qian P, Jiang LL, Wang Y, Jin X, Zhang DF. Effect of betulonic acid on proliferation of human breast cancer MCF-7 cells and human cervical cancer C-33A cells. Pract Pharm Clin Remedies. 2017;20:254\u20137.","journal-title":"Pract Pharm Clin Remedies"},{"key":"3143_CR7","first-page":"64","volume":"35","author":"Z Lai","year":"1996","unstructured":"Lai Z, Dong Y. Studies on the chemical constituents of Lu Lu Tong (1) structure determination of a novel pentacyclic triterpene. Acta Sci Nat Univ Sunyatseni. 1996;35:64\u20139.","journal-title":"Acta Sci Nat Univ Sunyatseni"},{"key":"3143_CR8","first-page":"40","volume":"35","author":"Z Lai","year":"1996","unstructured":"Lai Z, Dong Y. Studies on the chemical constituents of Lu Lu Tong. (2). Acta Sci Nat Univ Sunyatseni. 1996;35:40\u20134.","journal-title":"Acta Sci Nat Univ Sunyatseni"},{"key":"3143_CR9","first-page":"437","volume":"31","author":"Y Sun","year":"1996","unstructured":"Sun Y, Sun Y. Structure elucidation of liquidambaric lactone. Acta Pharm Sin. 1996;31:437\u201340.","journal-title":"Acta Pharm Sin"},{"key":"3143_CR10","first-page":"1","volume":"11","author":"C Li","year":"2002","unstructured":"Li C, Sun Y, Sun Y. A new triterpene from the fruits of Liquidambar formosana Hance-Lulutong. J Chin Pharm Sci. 2002;11:1\u20134.","journal-title":"J Chin Pharm Sci"},{"key":"3143_CR11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1248\/bpb.27.426","volume":"27","author":"NT Dat","year":"2004","unstructured":"Dat NT, Lee IS, Cai XF, Shen G, Kim YH. Oleanane triterpenoids with inhibitory activity against NFAT transcription factor from Liquidambar formosana. Biol Pharm Bull. 2004;27:426\u20138.","journal-title":"Biol Pharm Bull"},{"key":"3143_CR12","first-page":"1207","volume":"45","author":"H Shang","year":"2014","unstructured":"Shang H, Wang W, Li D, Hua H, Li Z. A new triterpenoid isolated from fruits of Liquidambaris Fructus. Chin Tradit Herb Drugs. 2014;45:1207\u201310.","journal-title":"Chin Tradit Herb Drugs"},{"key":"3143_CR13","doi-asserted-by":"publisher","first-page":"W356","DOI":"10.1093\/nar\/gkx374","volume":"45","author":"X Wang","year":"2017","unstructured":"Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X, et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017;45:W356\u201360.","journal-title":"Nucleic Acids Res"},{"key":"3143_CR14","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1101\/gr.071852.107","volume":"18","author":"T Ideker","year":"2008","unstructured":"Ideker T, Sharan R. Protein networks in disease. Genome Res. 2008;18:644\u201352.","journal-title":"Genome Res"},{"key":"3143_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2105-4-2","volume":"4","author":"GD Bader","year":"2003","unstructured":"Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics. 2003;4:2.","journal-title":"BMC Bioinformatics"},{"key":"3143_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/415141a","volume":"415","author":"AC Gavin","year":"2002","unstructured":"Gavin AC, B\u00f6sche M, Krause R, Grandi P, Marzioch M, Bauer A, et al. Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature. 2002;415:141\u20137.","journal-title":"Nature"},{"key":"3143_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1126\/science.1064987","volume":"295","author":"AHY Tong","year":"2002","unstructured":"Tong AHY, Drees B, Nardelli G, Bader GD, Brannetti B, Castagnoli L, et al. A combined experimental and computational strategy to define protein interaction networks for peptide recognition modules. Science (80- ). 2002;295:321\u20134.","journal-title":"Science (80- )"},{"key":"3143_CR18","first-page":"1","volume":"20","author":"PHM Torres","year":"2019","unstructured":"Torres PHM, Sodero ACR, Jofily P, Silva-Jr FP. Key topics in molecular docking for drug design. Int J Mol Sci. 2019;20:1\u201329.","journal-title":"Int J Mol Sci"},{"key":"3143_CR19","doi-asserted-by":"publisher","first-page":"14235","DOI":"10.3390\/molecules190914235","volume":"19","author":"BN Irungu","year":"2014","unstructured":"Irungu BN, Orwa JA, Gruhnojic A, Fitzpatrick PA, Landberg G, Kimani F, et al. Constituents of the roots and leaves of Ekebergia capensis and their potential antiplasmodial and cytotoxic activities. Molecules. 2014;19:14235\u201346.","journal-title":"Molecules"},{"key":"3143_CR20","first-page":"508","volume":"11","author":"C Liu","year":"1991","unstructured":"Liu C, Xu JF, He QM, Yu QS. Chemical components of the Liquidambar formosana H. Resin Youji Huaxue. 1991;11:508\u201310.","journal-title":"Resin Youji Huaxue"},{"key":"3143_CR21","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0031-9422(00)89569-2","volume":"37","author":"SB Mahato","year":"1994","unstructured":"Mahato SB, Kundu AP. 13C NMR spectra of pentacyclic triterpenoids-a compilation and some salient features. Phytochemistry. 1994;37:1517\u201375.","journal-title":"Phytochemistry"},{"key":"3143_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/(SICI)1097-458X(199804)36:4<267::AID-OMR256>3.0.CO;2-6","volume":"36","author":"C Peng","year":"1998","unstructured":"Peng C, Bodenhausen G, Qiu S, Fong HHS, Farnsworth NR, Yuan S, et al. Computer-assisted structure elucidation: application of CISOC-SES to the resonance assignment and structure generation of betulinic acid. Magn Reson Chem. 1998;36:267\u201378.","journal-title":"Magn Reson Chem"},{"key":"3143_CR23","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1021\/ci300367a","volume":"52","author":"F Cheng","year":"2012","unstructured":"Cheng F, Li W, Zhou Y, Shen J, Wu Z, Liu G, et al. AdmetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model. 2012;52:3099\u2013105.","journal-title":"J Chem Inf Model"},{"key":"3143_CR24","doi-asserted-by":"publisher","first-page":"D1121","DOI":"10.1093\/nar\/gkx1076","volume":"46","author":"YH Li","year":"2018","unstructured":"Li YH, Yu CY, Li XX, Zhang P, Tang J, Yang Q, et al. Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics. Nucleic Acids Res. 2018;46:D1121\u20137.","journal-title":"Nucleic Acids Res"},{"key":"3143_CR25","doi-asserted-by":"publisher","first-page":"D158","DOI":"10.1093\/nar\/gkw1099","volume":"45","author":"The UniProt Consortium","year":"2017","unstructured":"The UniProt Consortium. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 2017;45:D158\u201369. https:\/\/doi.org\/10.1093\/nar\/gkw1099.","journal-title":"Nucleic Acids Res"},{"key":"3143_CR26","doi-asserted-by":"publisher","first-page":"D362","DOI":"10.1093\/nar\/gkw937","volume":"45","author":"D Szklarczyk","year":"2017","unstructured":"Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein\u2013protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45:D362\u20138. https:\/\/doi.org\/10.1093\/nar\/gkw937.","journal-title":"Nucleic Acids Res"},{"key":"3143_CR27","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498\u2013504. https:\/\/doi.org\/10.1101\/gr.1239303.","journal-title":"Genome Res"},{"key":"3143_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data Bank. Nucleic Acids Res. 2000;28:235\u201342. https:\/\/doi.org\/10.1093\/nar\/28.1.235.","journal-title":"Nucleic Acids Res"},{"key":"3143_CR29","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/bioinformatics\/btp101","volume":"25","author":"G Bindea","year":"2009","unstructured":"Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25:1091\u20133. https:\/\/doi.org\/10.1093\/bioinformatics\/btp101.","journal-title":"Bioinformatics"},{"key":"3143_CR30","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/bioinformatics\/btt019","volume":"29","author":"G Bindea","year":"2013","unstructured":"Bindea G, Galon J, Mlecnik B. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics. 2013;29:661\u20133. https:\/\/doi.org\/10.1093\/bioinformatics\/btt019.","journal-title":"Bioinformatics"},{"key":"3143_CR31","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.celrep.2013.03.027","volume":"3","author":"M Varjosalo","year":"2013","unstructured":"Varjosalo M, Keskitalo S, VanDrogen A, Nurkkala H, Vichalkovski A, Aebersold R, et al. The protein interaction landscape of the human CMGC kinase group. Cell Rep. 2013;3:1306\u201320. https:\/\/doi.org\/10.1016\/j.celrep.2013.03.027.","journal-title":"Cell Rep"},{"key":"3143_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0797-x","volume":"17","author":"R Butti","year":"2018","unstructured":"Butti R, Das S, Gunasekaran VP, Yadav AS, Kumar D, Kundu GC. Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Mol Cancer. 2018;17:1\u201318.","journal-title":"Mol Cancer"},{"key":"3143_CR33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1146\/annurev.biochem.69.1.373","volume":"69","author":"SR Hubbard","year":"2000","unstructured":"Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem. 2000;69:373\u201398. https:\/\/doi.org\/10.1146\/annurev.biochem.69.1.373.","journal-title":"Annu Rev Biochem"},{"key":"3143_CR34","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/jcp.56.4.300","volume":"56","author":"AJ Lodge","year":"2003","unstructured":"Lodge AJ, Anderson JJ, Gullick WJ, Haugk B, Leonard RCF, Angus B. Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4. J Clin Pathol. 2003;56:300\u20134.","journal-title":"J Clin Pathol"},{"key":"3143_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-015-2026-y","volume":"16","author":"JY Kim","year":"2016","unstructured":"Kim JY, Jung HH, Do IG, Bae SY, Lee SK, Kim SW, et al. Prognostic value of ERBB4 expression in patients with triple negative breast cancer. BMC Cancer. 2016;16:1\u201312.","journal-title":"BMC Cancer"},{"key":"3143_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","volume":"100","author":"R Roskoski","year":"2015","unstructured":"Roskoski R. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res. 2015;100:1\u201323. https:\/\/doi.org\/10.1016\/j.phrs.2015.07.010.","journal-title":"Pharmacol Res"},{"issue":"139","key":"3143_CR37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","volume":"2019","author":"R Roskoski","year":"2018","unstructured":"Roskoski R. Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. November 2018;2019(139):395\u2013411. https:\/\/doi.org\/10.1016\/j.phrs.2018.11.014.","journal-title":"Pharmacol Res"},{"key":"3143_CR38","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","volume":"76","author":"MT Herrera-Abreu","year":"2016","unstructured":"Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, et al. Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. 2016;76:2301\u201313.","journal-title":"Cancer Res"},{"key":"3143_CR39","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1158\/1078-0432.CCR-17-0369","volume":"23","author":"US Asghar","year":"2017","unstructured":"Asghar US, Barr AR, Cutts R, Beaney M, Babina I, Sampath D, et al. Single-cell dynamics determines response to CDK4\/6 inhibition in triple-negative breast cancer. Clin Cancer Res. 2017;23:5561\u201372.","journal-title":"Clin Cancer Res"},{"key":"3143_CR40","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","volume":"139","author":"R Roskoski","year":"2019","unstructured":"Roskoski R. Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs. Pharmacol Res. 2019;139:471\u201388. https:\/\/doi.org\/10.1016\/j.phrs.2018.11.035.","journal-title":"Pharmacol Res"},{"key":"3143_CR41","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S","volume":"95","author":"JMW Gee","year":"2001","unstructured":"Gee JMW, Robertson JFR, Ellis IO, Nicholson RI. Phosphorylation of ERK1\/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer. 2001;95:247\u201354. https:\/\/doi.org\/10.1002\/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S.","journal-title":"Int J Cancer"},{"key":"3143_CR42","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1002\/ijc.21707","volume":"118","author":"YT Yeh","year":"2006","unstructured":"Yeh YT, Hou MF, Chung YF, Chen YJ, Yang SF, Chen DC, et al. Decreased expression of phosphorylated JNK in breast infiltrating ductal carcinoma is associated with a better overall survival. Int J Cancer. 2006;118:2678\u201384.","journal-title":"Int J Cancer"},{"key":"3143_CR43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/cncr.11940","volume":"100","author":"FJ Esteva","year":"2004","unstructured":"Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, et al. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer. 2004;100:499\u2013506.","journal-title":"Cancer"},{"key":"3143_CR44","first-page":"1","volume":"10","author":"T Wu","year":"2015","unstructured":"Wu T, Wang X, Li J, Song X, Wang Y, Wang Y, et al. Identification of personalized chemoresistance genes in subtypes of basal-like breast cancer based on functional differences using pathway analysis. PLoS One. 2015;10:1\u201318.","journal-title":"PLoS One"},{"key":"3143_CR45","doi-asserted-by":"publisher","first-page":"11322","DOI":"10.1074\/jbc.M512546200","volume":"281","author":"G Chakraborty","year":"2006","unstructured":"Chakraborty G, Rangaswami H, Jain S, Kundu GC. Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis. J Biol Chem. 2006;281:11322\u201331.","journal-title":"J Biol Chem"},{"key":"3143_CR46","doi-asserted-by":"publisher","first-page":"35237","DOI":"10.1074\/jbc.M113.490235","volume":"288","author":"C Sibilski","year":"2013","unstructured":"Sibilski C, Mueller T, Kollipara L, Zahedi RP, Rapp UR, Rudel T, et al. Tyr728 in the kinase domain of the murine kinase suppressor of RAS 1 regulates binding and activation of the mitogen-activated protein kinase kinase. J Biol Chem. 2013;288:35237\u201352.","journal-title":"J Biol Chem"},{"key":"3143_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers8120108","volume":"8","author":"R Narayanan","year":"2016","unstructured":"Narayanan R, Dalton JT. Androgen receptor: a complex therapeutic target for breast cancer. Cancers (Basel). 2016;8:1\u201317.","journal-title":"Cancers (Basel)"},{"key":"3143_CR48","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.gene.2018.01.018","volume":"649","author":"S Yousefnia","year":"2018","unstructured":"Yousefnia S, Momenzadeh S, Seyed Forootan F, Ghaedi K, Nasr Esfahani MH. The influence of peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) ligands on cancer cell tumorigenicity. Gene. 2018;649:14\u201322. https:\/\/doi.org\/10.1016\/j.gene.2018.01.018.","journal-title":"Gene"},{"key":"3143_CR49","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nature07614","volume":"457","author":"D Ghosh","year":"2009","unstructured":"Ghosh D, Griswold J, Erman M, Pangborn W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature. 2009;457:219\u201323. https:\/\/doi.org\/10.1038\/nature07614.","journal-title":"Nature"},{"key":"3143_CR50","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/ng1963","volume":"39","author":"SG Julien","year":"2007","unstructured":"Julien SG, Dub\u00e9 N, Read M, Penney J, Paquet M, Han Y, et al. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nat Genet. 2007;39:338\u201346.","journal-title":"Nat Genet"},{"key":"3143_CR51","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/febs.14724","volume":"286","author":"M Yu","year":"2019","unstructured":"Yu M, Liu Z, Liu Y, Zhou X, Sun F, Liu Y, et al. PTP1B markedly promotes breast cancer progression and is regulated by miR-193a-3p. FEBS J. 2019;286:1136\u201353.","journal-title":"FEBS J"},{"key":"3143_CR52","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.4155\/fmc-2018-0089","volume":"10","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Du Y. The development of protein tyrosine phosphatase1B inhibitors defined by binding sites in crystalline complexes. Future Med Chem. 2018;10:2345\u201367.","journal-title":"Future Med Chem"},{"key":"3143_CR53","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1016\/j.bmc.2016.06.035","volume":"24","author":"XQ Li","year":"2016","unstructured":"Li XQ, Wang LJ, Shi DY. The design strategy of selective PTP1B inhibitors over TCPTP. Bioorg Med Chem. 2016;24:3343\u201352. https:\/\/doi.org\/10.1016\/j.bmc.2016.06.035.","journal-title":"Bioorg Med Chem"},{"key":"3143_CR54","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.4155\/fmc.14.88","volume":"6","author":"S Butterworth","year":"2014","unstructured":"Butterworth S, Overduin M, Barr AJ. Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention. Future Med Chem. 2014;6:1423\u201337. https:\/\/doi.org\/10.4155\/fmc.14.88.","journal-title":"Future Med Chem"},{"key":"3143_CR55","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nm.2645","volume":"18","author":"N Aceto","year":"2012","unstructured":"Aceto N, Sausgruber N, Brinkhaus H, Gaidatzis D, Martiny-Baron G, Mazzarol G, et al. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med. 2012;18:529\u201337.","journal-title":"Nat Med"},{"key":"3143_CR56","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1021\/jm901645u","volume":"53","author":"X Zhang","year":"2010","unstructured":"Zhang X, He Y, Liu S, Yu Z, Jiang Z-X, Yang Z, et al. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). J Med Chem. 2010;53:2482\u201393. https:\/\/doi.org\/10.1021\/jm901645u.","journal-title":"J Med Chem"},{"key":"3143_CR57","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nm.2385","volume":"17","author":"Q Huang","year":"2012","unstructured":"Huang Q, Li F, Liu X, Li W, Shi W, Liu F, et al. Caspase 3-mediated repopulation of cancer cels after radiotherapy. Nat Med. 2012;17:860\u20136.","journal-title":"Nat Med"},{"key":"3143_CR58","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrm3376","volume":"13","author":"BA Gibson","year":"2012","unstructured":"Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly (ADP-ribose) and PARPs. Nat Rev Mol Cell Biol. 2012;13:411\u201324.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3143_CR59","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ctrv.2017.11.003","volume":"62","author":"A Lee","year":"2018","unstructured":"Lee A, Djamgoz MBA. Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev. 2018;62:110\u201322. https:\/\/doi.org\/10.1016\/j.ctrv.2017.11.003.","journal-title":"Cancer Treat Rev"},{"issue":"December","key":"3143_CR60","first-page":"301","volume":"3","author":"JD Steffen","year":"2013","unstructured":"Steffen JD, Brody JR, Armen RS, Pascal JM. Structural implications for selective targeting of PARPs. Front Oncol. 2013;3(December):301.","journal-title":"Front Oncol"},{"key":"3143_CR61","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.canlet.2010.10.014","volume":"332","author":"G Jego","year":"2013","unstructured":"Jego G, Hazoum\u00e9 A, Seigneuric R, Garrido C. Targeting heat shock proteins in cancer. Cancer Lett. 2013;332:275\u201385. https:\/\/doi.org\/10.1016\/j.canlet.2010.10.014.","journal-title":"Cancer Lett"},{"key":"3143_CR62","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/nrd2656","volume":"7","author":"A Vazquez","year":"2008","unstructured":"Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov. 2008;7:979\u201387.","journal-title":"Nat Rev Drug Discov"},{"key":"3143_CR63","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1158\/0008-5472.CAN-05-3767","volume":"67","author":"JM Park","year":"2007","unstructured":"Park JM, Kanaoka Y, Eguchi N, Aritake K, Grujic S, Materi AM, et al. Hematopoietic prostaglandin D synthase suppresses intestinal adenomas in Apc min\/+ mice. Cancer Res. 2007;67:881\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-3767.","journal-title":"Cancer Res"},{"key":"3143_CR64","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/ijc.29392","volume":"137","author":"T Fukuoka","year":"2015","unstructured":"Fukuoka T, Yashiro M, Kinoshita H, Morisaki T, Hasegawa T, Hirakawa T, et al. Prostaglandin d synthase is a potential novel therapeutic agent for the treatment of gastric carcinomas expressing PPAR\u03b3. Int J Cancer. 2015;137:1235\u201344.","journal-title":"Int J Cancer"},{"key":"3143_CR65","first-page":"1739","volume":"33","author":"XJ Zhang","year":"2008","unstructured":"Zhang XJ, Han L, Ji YB, Fang GZ. Studies of betulonic acid on cell cycle and related protein expression on mice of bearing H22 tumor cells. China J Chin Mater Medica. 2008;33:1739\u201343.","journal-title":"China J Chin Mater Medica"},{"key":"3143_CR66","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.phymed.2016.12.018","volume":"26","author":"KH Leong","year":"2017","unstructured":"Leong KH, Mahdzir MA, Din MFM, Awang K, Tanaka Y, Kulkeaw K, et al. Induction of intrinsic apoptosis in leukaemia stem cells and in vivo zebrafish model by betulonic acid isolated from Walsura pinnata Hassk (Meliaceae). Phytomedicine. 2017;26:11\u201321. https:\/\/doi.org\/10.1016\/j.phymed.2016.12.018.","journal-title":"Phytomedicine"},{"key":"3143_CR67","doi-asserted-by":"publisher","first-page":"112228","DOI":"10.1016\/j.phytochem.2019.112228","volume":"171","author":"H Zhang","year":"2020","unstructured":"Zhang H, Kang Y, Li N, Wang H, Bao Y, Li Y, et al. Triterpenoids from Liquidambar Fructus induced cell apoptosis via a PI3K-AKT related signal pathway in SMMC7721 cancer cells. Phytochemistry. 2020;171:112228. https:\/\/doi.org\/10.1016\/j.phytochem.2019.112228.","journal-title":"Phytochemistry"},{"key":"3143_CR68","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrc2787","volume":"10","author":"ZA Knight","year":"2010","unstructured":"Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer. 2010;10:130\u20137.","journal-title":"Nat Rev Cancer"},{"key":"3143_CR69","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.semcancer.2013.06.003","volume":"23","author":"S Huang","year":"2013","unstructured":"Huang S, Kauffman S. How to escape the cancer attractor: rationale and limitations of multi-target drugs. Semin Cancer Biol. 2013;23:270\u20138. https:\/\/doi.org\/10.1016\/j.semcancer.2013.06.003.","journal-title":"Semin Cancer Biol"},{"key":"3143_CR70","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.ejmech.2017.10.021","volume":"143","author":"NM Raghavendra","year":"2018","unstructured":"Raghavendra NM, Pingili D, Kadasi S, Mettu A, Prasad SVUM. Dual or multi-targeting inhibitors: the next generation anticancer agents. Eur J Med Chem. 2018;143:1277\u2013300. https:\/\/doi.org\/10.1016\/j.ejmech.2017.10.021.","journal-title":"Eur J Med Chem"},{"key":"3143_CR71","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429\u201334.","journal-title":"Clin Cancer Res"},{"key":"3143_CR72","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10911-008-9076-6","volume":"13","author":"FE Jones","year":"2008","unstructured":"Jones FE. HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. J Mammary Gland Biol Neoplasia. 2008;13:247\u201358.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"3143_CR73","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/378390a0","volume":"378","author":"M Gassmann","year":"1995","unstructured":"Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R, et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature. 1995;378:390\u20134. https:\/\/doi.org\/10.1038\/378390a0.","journal-title":"Nature"},{"key":"3143_CR74","doi-asserted-by":"publisher","first-page":"628","DOI":"10.2174\/138955708784534454","volume":"8","author":"M Meyn III","year":"2008","unstructured":"Meyn M III, Smithgall T. Small molecule inhibitors of Lck: the search for specificity within a kinase family. Mini Rev Med Chem. 2008;8:628\u201337.","journal-title":"Mini Rev Med Chem"},{"key":"3143_CR75","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1021\/np50052a022","volume":"50","author":"BL Poehland","year":"1987","unstructured":"Poehland BL, Cart\u00e9 BK, Francis TA, Hyland LJ, Allaudeen HS, Troupe N. In vitro antiviral activity of dammar resin triterpenoids. J Nat Prod. 1987;50:706\u201313. https:\/\/doi.org\/10.1021\/np50052a022.","journal-title":"J Nat Prod"},{"key":"3143_CR76","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0031-9422(96)00266-X","volume":"43","author":"N Shirane","year":"1996","unstructured":"Shirane N, Hashimoto Y, Ueda K, Takenaka H, Katoh K. Ring-a cleavage of 3-oxo-olean-12-en-28-oic acid by the fungus Chaetomium longirostre. Phytochemistry. 1996;43:99\u2013104.","journal-title":"Phytochemistry"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-020-03143-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12906-020-03143-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-020-03143-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T10:03:29Z","timestamp":1606471409000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-020-03143-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,27]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3143"],"URL":"https:\/\/doi.org\/10.1186\/s12906-020-03143-8","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,27]]},"assertion":[{"value":"6 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"369"}}